Lamivudine/maraviroc/zidovudine

Drug Profile

Lamivudine/maraviroc/zidovudine

Alternative Names: GSK 2838510; Lamivudine/zidovudine/maraviroc; Maraviroc/lamivudine/zidovudine; Maraviroc/zidovudine/lamivudine; Zidovudine/lamivudine/maraviroc; Zidovudine/maraviroc/lamivudine

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator GlaxoSmithKline
  • Class Antiretrovirals; Azides; Cyclohexanes; Deoxyribonucleosides; Pyrimidine nucleosides; Small molecules; Triazoles
  • Mechanism of Action CCR5 receptor antagonists; Nucleoside reverse transcriptase inhibitors; Virus internalisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported HIV-1 infections

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in HIV-1-infections(In volunteers) in USA (PO, Tablet)
  • 31 Jan 2012 GlaxoSmithKline completes a Phase-I bioequivalence trial in HIV-1 infections (in volunteers) in USA (NCT01597648)
  • 01 Nov 2011 Phase-I clinical trials in HIV-1 infections (in volunteers) in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top